Table 1 Clinical application of cfDNA/ctDNA in T cell lymphoma
From: Liquid biopsy in T-cell lymphoma: biomarker detection techniques and clinical application
Lymphoma subtypes | Author | PMID/doi | Biomarker | Liquid Biopsy | Method | No. of patients | Results | Clinical applications |
|---|---|---|---|---|---|---|---|---|
nTFHL-AI, PTCL, NOS | Sakata-Yanagimoto M et al. [26] | 28634614 | ctDNA | PB | NGS, 4 genes targeted sequencing | 14 | TET2, RHOA G17V, DNMT3A, and IDH2 mutation of ctDNAs is a good candidate for diagnosis | diagnostic |
nTFHL-AI | Hayashida, Masahiko et al. [27] | 32476550 | cfDNA | PB | AS-PCR | 20 | combination of multicolor FCM and RHOAG17V and IDH2R172 hot-spot mutations in plasma cfDNA diagnosis of nTFHL-AI | diagnostic |
nTFHL-AI, PTCL, NOS, ALCL | Ottolini, Barbara et al. [28] | 32484856 | cfDNA | PB | WES, NGS 81(CAPP-seq) and 12 genes targeted sequencing, ddPCR, Sanger sequencing | 25 | sequencing of RHOA from cfDNA has revealed new mutations and haplotypes RHOA c.73A > G (p.Phe25Leu) and c.48A > T (p.Cys16*) | diagnostic |
ENKTL | Li, Qiong et al. [29] | 32695399 | ctDNA | PB | NGS, 41 genes targeted sequencing | 65 | mutated KMT2D and ATM predicted poor OS, P = 0.001, P = 0.001 | prognosis |
nTFHL-AI, ALCL, PTCL, NOS | Herrera, Alex F et al. [30] | 27711974 | ctDNA | PB | NGS, IGH VDJ, IGH DJ, IGK, TCR-β, TCR-δ, TCR-γ | 68 | 84% patients had detectable ctDNA prior to progression at a median of 3.7 months. Patients with detectable ctDNA 3 months, 2-year PFS 58% vs. 84% P = 0.033) | longitudinal monitoring, MRD |
PTCL, NOS, ALCL, nTFHL-AI, SS, SPTCL | Zhang, Wei et al. [31] | 33734593 | ctDNA | PB | mPCR, NGS, CDR3 of TCRβ chains | 23 | high level of ctDNA predicted treatment failure (P = 0.0003), ctDNA changed in concordance with clinical outcome and was more sensitive than PET/CT | longitudinal monitoring |
PTCL, NOS, ALCL, nTFHL-AI | Miljkovic, Milos D et al. [32] | 34432874 | ctDNA(TCRβ, TCRγ) | PB | NGS, CDR3 of the TCRβ/TCRγ genes | 45 | patients with detectable ctDNA after therapy showed a trend toward worse survival. EFS, P = 0.083 | longitudinal monitoring, MRD |
T-LBL | Chen, Feili et al. [33] | 32431543 | ctDNA | PB | NGS, 102 genes targeted sequencing | 43 | 92.6% agreement between ctDNA response and tumor volume measurements at post treatment when compared with baseline | longitudinal monitoring |
ENKTL | Qi, Fei et al. [34] | 34047776 | cfDNA | PB | NGS, 112 genes targeted sequencing | 24 | cfDNA clearance vs no clearance, complete remission rates (80.0% vs 0%; P = 0.004), 1-year PFS, 79.0% vs 20.0%; P = 0.002). low cfDNA concentration before treatment (1-year PFS, 90.0% vs 36.4%; P = 0.012) | longitudinal monitoring, prognosis |
PTCL, NOS, ALCL, nTFHL-AI | Kim, S.J. et al. [35] | 35240014 | ctDNA | PB | NGS, 66 genes targeted sequencing | 94 |  ≥ 1.5-log decrease in GE showed better PFS and OS, P = 0.027, P = 0.003 | longitudinal monitoring |